A Silicon Valley-based VC fund is focused on early-stage ( Seed, Series A/B ) AI companies in Healthcare, Enterprise, and Automation. With a mission-driven thesis of doing well by doing good, the firm invest in technical founders keen on applying AI to solve some of the acutest problems faced across industries. The firm is currently investing from its second fund which is focusing on applied AI for Healthcare ( Precision Medicine, AI Drug Development, Gene/Cell Therapies Delivery, Oncology, Medical Imaging, Digital Healthcare), Enterprise ( Co-Pilots for Enterprise, Cybersecurity, DevOps/MLOps Tools, Infrastructure), and Automation ( Robotics, Autonomous Driving, Drones ).
The firm’s team is a multidisciplinary team of seasoned founders, deep technologists/scientists, and healthcare practitioners united by a drive to nurture the next wave of startups transforming lives through AI.
The firm can invest from Seed to Series B rounds with check size ranging from $250k-4M USD. The firm focuses on companies in the U.S., Canada, and the U.K.
In terms of healthcare, the firm invests in companies that blend technology toward healthcare applications; what the firm likes to call “tech-bio”. Some examples include technology that can improve how drugs are discovered, targeted and delivered, that drive clinical results with biased-free patient selection and data transparency, digital therapeutics and precision medicine. The goal is to improve patient outcomes and serve multiple customers and pipelines. The firm is not interested in traditional assets.
The firm prefers to take a board seat however, it is not required.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment